Since the introduction of reduced-intensity stem-cell transplantation (RIST), allogeneic stem-cell transplantation has become available for elderly patients. While pharmacokinetics of cyclosporine might differ according to age or other factors, cyclosporine is uniformly started at an oral dose of 6 mg/kg/day. We retrospectively reviewed medical records of 35 patients aged between 32 and 65 (median 52) years who had undergone RIST. Doses of cyclosporine were adjusted to the target blood trough level of 150-250 ng/ml. Cyclosporine dosages were changed in 33 patients (94%). Dose reduction was required in 32 patients because of high blood levels (n ¼ 25), renal dysfunction (n ¼ 3), hepatic dysfunction (n ¼ 2), and hypertension (n ¼ 2). Cyclosporine doses were increased in one because of the suboptimal level. The median of the achieved stable doses was 3.1 mg/kg/day (range, 1.0-7.4). Five patients sustained Grade III toxicities according to NCI-CTC version 2.0: renal dysfunction (n ¼ 4), hyperbilirubinemia (n ¼ 2), and hypertension (n ¼ 2). No patients developed grade IV toxicity. There was no statistically significant difference in the frequency and severity of cyclosporine toxicities between patients aged 50 years and above and those below 50 years. The initial oral cyclosporine dose of 6 mg/kg/day was unnecessarily high irrespective of age. The possible overdose of cyclosporine might have aggravated regimen-related toxicities.
geneic hematopoietic stem cell transplantation, calcineurin inhibitor Cyclosporine is commonly started at a dose of 6 mg/kg/day via oral routes or 3 mg/kg/day via intravenous routes in reduced intensity stem cell transplantation (RIST) as well as conventional allogeneic hematopoietic stem cell transplantation (allo-HSCT).
1,2 However, its pharmacokinetics might differ according to various factors including age, and there is no solid evidence to support applying a fixed conventional starting dose of cyclosporine to every individual. Since the introduction of RIST, more elderly patients have become candidates for allo-HSCT. No reports have addressed optimal cyclosporine dose in elderly patients undergoing RIST. Only a few reports have been published concerning cyclosporine pharmacokinetics in elderly individuals. 3, 4 Single dose studies have demonstrated that cyclosporine pharmacokinetics are not different in healthy elderly individuals compared to healthy young adults, nor is the between-subject variability in pharmacokinetic parameters more heterogeneous in healthy elderly individuals. 3 A population pharmacokinetic study of cyclosporine in organ transplant patients, including elderly allograft recipients up to 75 years of age, did not identify age as a covariate influencing cyclosporine pharmacokinetics. 3 These studies failed to show a significant association between cyclosporine disposition and the patients' ages. The association has never been investigated in the setting of allo-HSCT. The objective of this study was to evaluate the appropriateness of starting oral cyclosporine at a dose of 6 mg/kg/day in RIST in relation to target trough level and its toxicities especially in relation to age by comparing patients at the age of 50 years and above and those below 50 years.
Patients and methods

Patients
The medical records of all of the patients who underwent RIST at the National Cancer Center Hospital and Toranomon Hospital between January 2000 and September 2003 were reviewed. All patients and donors gave their written informed consent in accordance with the requirements of the Institutional Review Board. A total of 35 patients in whom cyclosporine was started orally at a dose of 6 mg/kg/day were enrolled. The median age of these patients was 52 (range, 32-65) years. Primary diseases consisted of acute myeloblastic leukemia (n ¼ 8), malignant lymphoma (n ¼ 9), myelodysplastic syndrome (n ¼ 3), acute lymphoblastic leukemia (n ¼ 1), other hematologic diseases (n ¼ 3) and solid tumors (n ¼ 11).
Transplantation procedures
Reduced intensity preparative regimens were busulfan at 4 mg/kg for 2 days and fludarabine at 25 mg/kg for 6 days (n ¼ 30), and busulfan at 4 mg/kg for 2 days and cladribine at 0.11 mg/kg. for 6 days (n ¼ 5).
5 Rabbit antithymocyte globulin (ATG, Thymoglobulin, Imtix-Sangstat, Lyons, France) at 2.5 mg/kg for 2 or 4 days, and total body irradiation 4 Gy were added to the preparative regimens in five and two patients, respectively.
The stem cell sources were an HLA-identical related donor (n ¼ 32), a one-locus mismatched related donor (n ¼ 1), and a matched unrelated donor (MUD) (n ¼ 2). Peripheral blood and marrow were transfused in RIST from related donors and that from a matched unrelated donor (MUD), respectively. All the patients received fluconazole at 200 mg for fungal prophylaxis until withdrawal of cyclosporine.
Administration of cyclosporine and monitoring of blood cyclosporine levels
All the patients received oral cyclosporine (NeoralTM, Novartis, Switzerland) at 3 mg/kg every 12 h, beginning on day À1. Short-term methotrexate was added to the GVHD prophylaxis in RIST from an HLA-mismatched related donor or MUD.
Blood levels of cyclosporine were monitored at least once a week. The blood samples were treated with EDTA anticoagulants, and the concentration of cyclosporine in whole blood was determined by fluorescence polarization immunoassay (FPI) with a specific monoclonal antibody. 6 Dosages of cyclosporine were adjusted according to its blood concentration and serum levels of creatinine. 7 The dose of cyclosporine and target therapeutic blood concentration vary widely in different centers. 8 In Japan, where incidence of acute GVHD is low compared with the Western countries, 9 the trough target range of cyclosporine 150-250 ng/ml is recommended by the Japan Society for Hematopoietic Stem Cell Transplantation http:// www.jshct.com/guide_pdf/1999gvhv2.pdf.
Study end points and statistical analysis
The primary objective of this study was to evaluate the feasibility of oral cyclosporine starting at a dose of 6 mg/kg/ day in RIST. We examined the proportion of patients in which cyclosporine was discontinued or its dosages were changed within 28 days of transplant. The other objective was to investigate the incidence of common cyclosporine toxicity: elevation of blood creatinine levels, hyperbilirubinemia, hyperkalemia, hypomagnesemia, and hypertension. These variables were compared between patients below age 50 years and those at 50 years and above. A univariate analysis using the w 2 chi-square test and Mann-Whitney test were performed. Cumulative incidence of acute GVHD was calculated using Gray's method, 10 treating deaths without GVHD as a competing risk. Potential confounding factors considered in the analysis were age, sex, stem cell dose, HLA disparity, transplantation from an alternative donor, conditioning regimen and through levels of cyclosporine (below 150 ng/ml vs. higher than 150 ng/mL). Proportional hazard modeling was used to evaluate the influence of these factors on the incidence of acute GVHD using the proportional hazard modeling treating serum levels of cyclosporine as time-dependent covariates. P-values of less than 0.05 were considered statistically significant.
Results
Changes of cyclosporine dosages
Cyclosporine dosages were changed in 33 patients (94%) (Figure 1 ). Dose reduction was required in 32 patients (91%) because of high blood levels of cyclosporine (n ¼ 25), renal dysfunction (n ¼ 3), hepatic dysfunction (n ¼ 2), hypertension (n ¼ 2). Renal dysfunction progressed to acute renal failure in one patient after cessation of cyclosporine. Dosages of cyclosporine were increased in the other patient (3%), because blood levels of cyclosporine were below its target.
At the initial monitoring of cyclosporine, its median levels were 219 ng/ml (range, 80-403) in the whole population; 206 ng/ml (range, 93-403) and 232 ng/ml (range, 80-372) in patients below 50 years and those at 50 years and above, respectively (P ¼ 0.50). Changes of cyclosporine concentration were shown in Figure 1 . Median interval between the initiation of cyclosporine and its initial dose adjustment was 15 days (range, 3-29). Stable dose of cyclosporine was 3.2 mg/kg/day (range, 1.0-7.4); 2.7 mg/kg/ 
Toxicity
All the patients developed grade I toxicities or more (Table 1 ). Grade III toxicities were shown in five patients: renal dysfunction (n ¼ 4), hyperbilirubinemia (n ¼ 2), and hypertension (n ¼ 2). No patients developed grade IV toxicity. As shown in Table 1 , there was no significant difference in frequency and severity of cyclosporine toxicities between patients at 50 years and above and those under 50 years. There was no significant difference in peak blood levels of cyclosporine within 28 days of transplant between patients with grade III or higher toxicities (median 369 ng/ml; range, 296-483) and those without them (median 361 ng/ml; range, 222-697) (P ¼ 0.47).
Acute GVHD
The cumulative incidence of grade I-IV acute GVHD was 43% (Figure 2 ). Median onset of GVHD was day 29 (range, 12-72). Median blood level of cyclosporine was 183 ng/ml (range, 25-340) at the onset of acute GVHD. Within 28 days of transplant, blood levels of cyclosporine below 150 ng/ml were documented in seven of 15 patients who developed acute GVHD within 35 days of transplant and seven of 20 patients who had not developed it (P ¼ 0.51). Any variables including blood levels of cyclosporine was not a significant risk factor for GVHD, when blood cyclosporine levels were treated as a time-dependent covariate.
Discussion
This study urged us to reconsider the starting dose of cyclosporine in allo-HSCT recipients. At our institutions, cyclosporine is started at the two-divided dose of 6 mg/kg/ day orally, and its trough levels are maintained between 150 and 250 ng/ml by FPI. This is a common practice in cyclosporine use in allo-HSCT in Japan. It is to be noted that the dose of cyclosporine was decreased in 33 of the 35 patients, and that the median dose of cyclosporine was settled at 3.1 mg/kg/day. These findings indicate that the starting dose of 6 mg/kg/day of oral cyclosporine is too high irrespective of age. It is reasonable to assume that an overdose of cyclosporine might have aggravated regimenrelated toxicities following RIST. Most allo-HSCT recipients are given azole antifungals, which inhibit CYP enzymes, elevating blood cyclosporine concentration. When we discussed the optimal starting dose of cyclosporine, we must consider clearance of cyclosporine, which decreases over time during the first 2 weeks after transplantation. 11, 12 When the constant cyclosporine clearance during days 22-60 is 1.00, the clearance during days 0-7, 8-14, 15-21 are 1.46, 1.32, and 1.20, respectively.
11
The change of clearance in the natural course of transplant recipients may be related to our observation that cyclosporine levels were elevated in many patients, requiring dose reduction. However, the present study showed that cyclosporine levels exceeded the target levels within a week in some patients, necessitating dose reduction (Figure 1) . The median day of cyclosporine dose reduction was day 14, when the decrease in its clearance was only 9.6%. 11 The change of clearance cannot fully explain the dose reduction requirement. When the target range of cyclosporine levels is determined at 150-250 ng/ml as in the Japanese standard, the starting dose of 6 mg/kg is probably unnecessarily high. The metabolism of CSP is still unclear and the target CSP levels vary among institutions. 8 Optimal target levels also remains unclear without convincing evidence. Further investigations to define target levels and the optimal starting dose are awaited.
While some conflicting reports have been published on cyclosporine toxicities in elderly patients, 3, 13 the incidence and severity of cyclosporine toxicities were similar between Table 1 Cyclosporine-related toxicity within 28 days of transplant (NCI-CTC version 2.0)
Elevation of blood creatinine levels 1  4  8  2  1  3  0  0  Hyperbilirubinemia  4  10  3  4  0  2  0  0  Hypertension  0  0  12  15  0  2  0  0  Hypomagnesemia  7  8  3 Oral CSP in RIST Y Kishi et al patients aged below 50 years and those at 50 years and above in this study. Previous studies demonstrate a reduction of in vitro and in vivo drug metabolism with age in humans, 14 and this tendency is prominent in patients above 70 years.
14 Lack of association between cyclosporine toxicity and patients' ages in this study might have been attributable to the fact that all of the patients enrolled in this study were younger than 70 years. Considering that most patients who receive RIST are younger than 70 years, the aging process itself might not have any apparent effect on the pharmacokinetics of cyclosporine or its variability in RIST.
This study provides valuable information on cyclosporine use for elderly patients; however, it has several problems to be discussed. First, this study is a retrospective chart review. We analyzed patients with heterogeneous backgrounds, and we cannot deny the possibility of unrecognized bias. The second problem is the reliability of the diagnosis of cyclosporine toxicity. Some common adverse events of cyclosporine such as renal dysfunction and jaundice were examined; however, these toxicities might have been attributable to either concomitant drugs or allogeneic immune reactions. Since allo-HSCT recipients receive multiple drugs, and GVHD is a common complication, it is theoretically impossible to differentiate cyclosporine toxicity from allogeneic immune reactions and toxicities caused by drugs other than cyclosporine. Last is the risk of acute GVHD, which rises as cyclosporine concentration falls. 15 Considering the low incidence of acute GVHD in Japanese allo-SCT recipients, 9 the low levels of cyclosporine targeted might have increased the incidence of acute GVHD in the present study. Further large-sized prospective evaluation is warranted to accurately evaluate cyclosporine toxicity and risk of GVHD in elderly patients.
